TREMFYA ® is the first and only approved, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23. IL-23 is a cytokine secreted by ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the first drug in the class available in both intravenous and subcutaneous ...

The overall performance of IL-23 p19 inhibitors for the treatment of IBD was evaluated by the systematic review and meta-analysis in this study. Objective: The objective of this study was to combine ...

Over the past decade, IL-23 inhibitors have gained significant prominence in the treatment of psoriasis. Natural products have emerged as potential modulators of IL-23 activity, particularly in the ...

Johnson & Johnson (J&J) has shared positive long-term results from a phase 3 trial of its dual-acting IL-23 inhibitor Tremfya ...

The company noted that TREMFYA is positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks.

A real-world study finds elderly psoriasis patients treated with IL-17 and IL-23 inhibitors achieve comparable long-term ...

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...